First introduced in 1950s, the flow cytometry technique has gained significant attention in the past few decades. This can be attributed to the fact that flow cytometry has been demonstrated to be capable of overcoming various challenges associated with conventional analytical techniques, such as western blotting and immunohistochemistry. The key concerns related to traditional approaches include low specificity and sensitivity, time and cost intensive procedures, higher chances of producing false results. Specifically, flow cytometry offers several advantages over the conventional methods intended for single cell analysis. For instance, using microscopy, about 6 parameters of a single cell can be detected, whereas a flow cytometer enables the detection of up to 30 distinct parameters.
In addition, the modern flow cytometer is capable of processing over 10,000 cells per second, thereby, enabling scientists to rapidly analyze and characterize millions of cells. Currently, flow cytometry is used in a number of applications in the medical industry, including assisting in evaluation of autoimmune disorders and infectious diseases, and diagnosis of leukemia and lymphoma. The increasing prevalence of chronic conditions has led to a rise in the number of focused research efforts being carried out; this has further created a considerable demand for advanced and rapid analytical techniques to better understand the disease morphology. In this context, the adoption of flow cytometry technique has witnessed considerable growth. However, this approach often requires the use of complex and expensive instruments, which need to be operated by highly trained professionals. Several small and mid-sized players usually do not have the resources to make such exorbitant investments. Therefore, outsourcing has emerged as a preferred operational model for flow cytometry innovators, who rely on specialty contract service providers to handle various aspects of flow cytometry related services.
At present, 30 players claim to offer a range of flow cytometry related services, including customized assay development services, manufacturing of consumables (such as dyes and buffers) used for analysis, analysis of various immune cells for various clinical and non-clinical studies, and cell line development. Further, 25 companies are currently engaged in the manufacturing of novel and advanced flow cytometers. To keep pace with the increasing demand for such services, players are not only actively undertaking initiatives to improve / expand their existing offerings but also entering into strategic partnerships with several industry stakeholders to broaden their respective services portfolios. For instance, in April 2021, Agilex Biolabs acquired TetraQ in order to further broaden its portfolio for analytical services offered via flow cytometry. Driven by the increasing number of clinical studies focused on evaluating treatment modalities against chronic disorders, we believe that the flow cytometry services market is likely to evolve at a steady pace in the foreseen future.
The “Flow Cytometry Services Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis, Bone Marrow Aspirate Analysis, Stem Cells Analysis, Rare Cells Detection, Cell Profiling and Subsetting and Intracellular Staining), Other types of Flow Cytometric Services, Type of Accreditations (Government and Third-Party Accreditations), Key Players, and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035”, report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of flow cytometry service providers market, in the mid to long term. The study includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from our secondary research.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
In addition, the modern flow cytometer is capable of processing over 10,000 cells per second, thereby, enabling scientists to rapidly analyze and characterize millions of cells. Currently, flow cytometry is used in a number of applications in the medical industry, including assisting in evaluation of autoimmune disorders and infectious diseases, and diagnosis of leukemia and lymphoma. The increasing prevalence of chronic conditions has led to a rise in the number of focused research efforts being carried out; this has further created a considerable demand for advanced and rapid analytical techniques to better understand the disease morphology. In this context, the adoption of flow cytometry technique has witnessed considerable growth. However, this approach often requires the use of complex and expensive instruments, which need to be operated by highly trained professionals. Several small and mid-sized players usually do not have the resources to make such exorbitant investments. Therefore, outsourcing has emerged as a preferred operational model for flow cytometry innovators, who rely on specialty contract service providers to handle various aspects of flow cytometry related services.
At present, 30 players claim to offer a range of flow cytometry related services, including customized assay development services, manufacturing of consumables (such as dyes and buffers) used for analysis, analysis of various immune cells for various clinical and non-clinical studies, and cell line development. Further, 25 companies are currently engaged in the manufacturing of novel and advanced flow cytometers. To keep pace with the increasing demand for such services, players are not only actively undertaking initiatives to improve / expand their existing offerings but also entering into strategic partnerships with several industry stakeholders to broaden their respective services portfolios. For instance, in April 2021, Agilex Biolabs acquired TetraQ in order to further broaden its portfolio for analytical services offered via flow cytometry. Driven by the increasing number of clinical studies focused on evaluating treatment modalities against chronic disorders, we believe that the flow cytometry services market is likely to evolve at a steady pace in the foreseen future.
Scope of the Report
The “Flow Cytometry Services Market by Type of General Flow Cytometric Services (Assay Development and Consumables Manufacturing), Type of Analysis based Flow Cytometric Services (PBMC Analysis, Whole Blood Cells Analysis, Bone Marrow Aspirate Analysis, Stem Cells Analysis, Rare Cells Detection, Cell Profiling and Subsetting and Intracellular Staining), Other types of Flow Cytometric Services, Type of Accreditations (Government and Third-Party Accreditations), Key Players, and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035”, report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of flow cytometry service providers market, in the mid to long term. The study includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
In addition to other elements, the report includes:
- A detailed review of the overall market landscape of the flow cytometry service providers, based on several relevant parameters, such as year of establishment, company size, location of headquarters, location of flow cytometry facilities, type of service(s) offered (general services, analysis services and other flow cytometric services). In addition, the chapter also provides information on the manufacturers and the respective flow cytometry equipment developed / being developed by them.
- A detailed competitiveness analysis of the flow cytometry service providers based across different geographies, by taking into consideration their service strength (based on number of services offered), accreditations (based on number of government and third-party accreditations) and supplier strength (based on total years of experience in the industry and company size).
- Tabulated profiles of key players offering services related to flow cytometry, based across various geographies. Each profile includes a brief overview of the company, financial information (if available), details on its services portfolio, types of services offered, location of flow cytometry facilities, recent developments and an informed future outlook.
- An analysis of the partnerships that have been inked by various stakeholders engaged in the field of flow cytometry, during the period 2011-2021, covering product development agreements, research and development agreements, licensing agreements, product commercialization agreements, platform utilization agreement, technology integration agreements and other relevant types of deals.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from our secondary research.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the leading players offering services related to flow cytometry?
- What is the relative competitiveness of the players offering services related to flow cytometry, based across different geographies?
- What are the type of services being offered by players engaged in the field of flow cytometry?
- What are the key trends in the flow cytometry service providers market?
- What kind of initiatives are being taken by stakeholders engaged in the flow cytometry domain?
- How is the current and future opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to the flow cytometry services market?
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN NORTH AMERICA
7. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN EUROPE
8. COMPANY PROFILES: FLOW CYTOMETRY SERVICE PROVIDERS IN ASIA-PACIFIC
9. PARTNERSHIPS AND COLLABORATIONS
10. EFFICIENCY COMPARISON MODULE
11. MARKET FORECAST
12. CONCLUDING REMARKS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABS Laboratories
- Accelix
- Accuri Cytometers
- ACEA Bioscience (Acquired by Agilent Technologies)
- ACM Global Laboratories
- Affymetrix (Acquired by Thermofisher Scientific)
- Agilent Technologies
- Agilex Biolabs
- AH diagnostics
- Akadeum Life Science
- AllCells
- Alverno Laboratories
- Amphasys
- ApogeeFlow
- BD
- Beckman Coulter
- Bio Legend
- bioMérieux
- Bio-Rad laboratories
- Blue Ocean Biomedical (Acquired by Beckman Coulter)
- Bucher Biotec
- Caprion Biosciences
- CellCarta
- Cellular Research
- CirQuest Labs (Acquired by MLM Medical Labs)
- Clearstone Central Laboratories
- CSI Laboratories
- Cytek Bioscience s
- Cytobank
- Cytognos
- Cytonome
- Cytonome
- DAON Biosciences
- De Novo Software
- Discovery and Drug Development Solutions (Division of Merck Millipore)
- Discovery Life Sciences
- EMBL
- Eurofins Bioanalytical Services
- Filgen
- Firalis
- Flow Contract Site Laboratory (FCSL)
- Flow Jo
- Flow Paradigm
- FlowMetric Life Sciences
- Genoptix
- Handeym
- Hematogenix
- HepaTX
- I&L Biosystems
- ICON Speciality Labs (formerly known as MolecularMD)
- iCyt Mission Technology
- Inabata
- IncellDX
- Invetech
- Invitrx Therapeutics
- KCAS Bioanlytical and Biomarker Services
- LabClinics
- LabCorp Drug Development
- Luminex
- Luxcel Biosciences
- Massachusetts General Hospital
- MD Biosciences
- Millenium Science
- Millipore Sigma
- Miltenyi Biotech
- Miltenyi Imaging (formerly known as Sensovation)
- MLM Medicine Labs
- Molecular Device
- Molecular MD
- Molecular Pathology Laboratory Network
- Myriad RBM
- Namocell
- NanoCellect Biomedical
- NanoFCM
- NeoGenomics Laboratories
- Nexcelom Bioscience
- Novogene
- Omega Biosystem (Acquired by California NanoSystems Institute)
- Omni Life Science
- On-Chip Biotechnologies
- Owl Biomedical
- Parnassus Flow Cytometry Core facility, University of California
- PHC Holdings
- Phitonex (Acquired by Thermofisher Scientific)
- ProImmune
- Propel Labs
- Q2 Solutions
- QualTek Molecular Laboratories (Acquired by Discovery Life Sciences)
- RAMCON
- RayBiotech
- ReachBio
- Real Matrix
- rqmicro
- Saltro (Acquired by Unilabs)
- Sartorius Stedim Biotech
- SBT Instruments
- Sirigen (Acquired by BD)
- Sony Biotechnology
- Stanford University
- Stratedigm
- Sumitomo Dainippon Pharma
- Suzhou Hybiome Biomedical Engineering
- Sysmex Inostics (Subsidiary of Sysmex)
- Sysmex Partec
- Takara Bio
- Terso Solutions
- TetraQ
- Texcell
- Thermo Fisher Scientific
- Tomy Digital Biology
- Unilabs
- Wyatt Technology
- Xitogen Technologies (Acquired by Beckman Coulter)
Methodology
LOADING...